Aruni Ghose: United Kingdom’s First Real World Evidence of Sacituzumab Govitecan in mTNBC
Aruni Ghose, Editorial Board Member at shared a post on LinkedIn:
“My favourite Registrar Mentor Daire Hanna led the United Kingdom’s (16 centres from England, Scotland, Wales) First Real World Evidence of the Antibody Drug Conjugate (ADC) Sacituzumab Govitecan (SG) in Metastatic Triple Negative Breast Cancer (mTNBC).
Third Authoring and contributing to this since inception with this team was an honour – Michael-John Devlin, Dorothy Yang, Edward Phillips, Alicia Okines, Elisavet Papadimitraki, Kirsty Ross, Caroline Michie, Sunnia Gupta, Tim Robinson, Lewis Germain, Chris Twelves, Charlotte Atkinson, Apostolos Konstantis, Pippa Riddle, Nicola Cresti, Jay Naik, Amy Guppy, Peter Schmid.
We started this project with Gilead Sciences in 2022 when 3/4 nations of the UK were using it as part of the compassionate use programme and access was not easy.
Daire then presented the data at ESMO – European Society for Medical Oncology Breast in 2023 and in between we saw this influencing NICE – National Institute for Health and Care Excellence Approval in August 2022.
It was a pleasure to see the hard work recently published in Nature Portfolio British Journal of Cancer.”
Read further.
Source: Aruni Ghose/LinkedIn